

GLAXOSMITHKLINE PLC

Form 6-K

March 02, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 02 March 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

#### Conditional Share Awards

On 1 March 2018, the Company granted awards to the Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) which was approved by shareholders on 4 May 2017.

Executive Directors are required to defer 50% of any bonus earned into Ordinary Shares or ADSs for a period of three years. Other participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs for the same period.

With effect from 2018, DABP Matching Awards are no longer granted.

The awards of deferred shares (Deferred Bonus Awards) have been granted as conditional awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The numbers of shares shown below are exclusive of dividend reinvestment that will accrue during the deferral period.

#### Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/  
amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Deferred Bonus Award of Ordinary Shares (under the

GlaxoSmithKline 2017  
Deferred Annual Bonus  
Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.072	58,889
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr R Connor
b) Position/status	President, Global Manufacturing & Supply

c) Initial notification/ amendment	Initial Notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
------------------------------	--

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.072	12,476
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr L Debruyne
b) Position/status	President, Global Vaccines

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument
- ISIN: GB0009252882
- Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
- b) Nature of the transaction

- |                             | Price(s)                 | Volume(s) |
|-----------------------------|--------------------------|-----------|
| c) Price(s) and volume(s)   | £13.072                  | 18,687    |
| d) Aggregated information   | n/a (single transaction) |           |
| Aggregated volume Price     |                          |           |
| e) Date of the transaction  | 2018-03-01               |           |
| f) Place of the transaction | n/a                      |           |

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction  
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.072	41,674

d) Aggregated information  
 Aggregated volume Price n/a (single transaction)

e) Date of the transaction 2018-03-01

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics and Compliance

c) Initial notification/  
 amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument  
 Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction  
 Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.072	6,543

- d) Aggregated information n/a (single transaction)
- Aggregated volume Price
- e) Date of the transaction 2018-03-01
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Miels
- b) Position/status President, Global  
Pharmaceuticals
- c) Initial notification/  
amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')
- ISIN: GB0009252882

Deferred Bonus Award of  
Ordinary Shares (under the  
GlaxoSmithKline 2017  
Deferred Annual Bonus  
Plan).

b) Nature of the transaction

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£13.072	11,848

- d) Aggregated information n/a (single transaction)
- Aggregated volume Price
- e) Date of the transaction 2018-03-01
- f) Place of the transaction n/a

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr B McNamara
  - b) Position/status CEO, GSK Consumer Healthcare
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument
 

American Depositary Shares ('ADSs')

ISIN: US37733W1053

Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
  - b) Nature of the transaction

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$36.31	6,320
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument  
ISIN: GB0009252882
- Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).
- b) Nature of the transaction
- |                             |                          |           |
|-----------------------------|--------------------------|-----------|
|                             | Price(s)                 | Volume(s) |
| c) Price(s) and volume(s)   | £13.072                  | 12,110    |
| d) Aggregated information   | n/a (single transaction) |           |
| e) Date of the transaction  | 2018-03-01               |           |
| f) Place of the transaction | n/a                      |           |

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/  
amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument  
ISIN: GB0009252882
- b) Nature of the transaction  
Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017



Deferred Annual Bonus  
Plan).

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£ 13.072	13,163
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr P Thomson
b) Position/status	President, Global Affairs
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
--	--

ISIN: GB0009252882

Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

b) Nature of the transaction

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.072	8,193
d) Aggregated information	n/a (single transaction)	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume Price  
 e) Date of the transaction 2018-03-01  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms K Terrell  
 b) Position/status Chief Digital & Technology Officer  
 c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 ISIN: US37733W1053

Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

b) Nature of the transaction

c) Price(s) and volume(s) Price(s) Volume(s)  
 \$36.31 2,137

d) Aggregated information n/a (single transaction)  
 Aggregated volume Price

e) Date of the transaction 2018-03-01  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D Troy  
 b) Position/status SVP & General Counsel  
 c) Initial notification/ Initial Notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')

- a) Description of the financial instrument

ISIN: US37733W1053

Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

- b) Nature of the transaction

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$36.31	7,349
d) Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P Vallance
- b) Position/status Outgoing President, R&D
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Deferred Bonus Award of  
Ordinary Shares (under the  
GlaxoSmithKline 2017  
Deferred Annual Bonus  
Plan).

b) Nature of the transaction

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.072	43,111
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 02, 2018

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc